During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. In this podcast, he discusses the recent updates from the KarMMa phase II trial (NCT03361748). in patients with relapsed/refractory multiple myeloma.
Nikhil Munshi describes the mechanism of action of the idecabtagene vicleucel (ide-cel) BCMA targeting CAR T-cell therapy before detailing the study design. He then provides results from the 128 patients enrolled in the study, including and dose-response rates, overall response rates, complete response rates, and MRD negativity rates. He also describes the safety profile including cytokine release syndrome, neurotoxicity and cytopenias. These results demonstrate deep and durable responses for a heavily pre-treated patient population with relapsed/refractory multiple myeloma.